Skip to main content

Uveitis clinical trials at UCSF
4 in progress, 2 open to new patients

  • Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

    open to eligible people ages 18 years and up

    The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6 month clinic visit. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week visit.

    San Francisco, California and other locations

  • Methotrexate and Mycophenolate Mofetil for UVEITIS

    open to eligible people ages 16 years and up

    In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uveitis in a block-randomized, observer-masked, comparative effectiveness trial.

    San Francisco, California and other locations

  • PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

    Sorry, currently not accepting new patients, but might later

    To evaluate the relative efficacy of three commonly utilized regional corticosteroids for the regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal triamcinolone acetonide; intravitreal dexamethasone implant. The primary efficacy measure will be percent change in central subfield thickness as measured by OCT at 8 weeks. Participants will continue in the study for 24 weeks in order to evaluate relative effects of the 3 treatment strategies on the duration of treatment effects, requirement for additional injections, and adverse effects.

    San Francisco, California and other locations

  • Topical Treatment for Uveitic Macular Edema

    Sorry, not yet accepting patients

    Macular edema is a condition in which there is swelling in the macula, the part of the retina that gives you your best vision. This swelling can cause your vision to get bad. When it is diagnosed early and treated, you vision usually can be preserved. However, if the swelling goes untreated for several months, it can cause permanent vision loss. We think that the three eye drop regimens in this study, difluprednate, prednisolone acetate, or nepafenac plus prednisolone acetate, might be effective in treating uveitic macular edema. Patients who enter this study are being randomized to one of the three regimens and are being followed for 24 weeks.

    San Francisco, California